Kinnate Biopharma Q3 EPS $(0.65) Beats $(0.67) Estimate
Portfolio Pulse from Benzinga Newsdesk
Kinnate Biopharma reported Q3 losses of $(0.65) per share, beating the analyst consensus estimate of $(0.67) by 2.99 percent. This is a 7.14 percent increase over losses of $(0.70) per share from the same period last year.
November 09, 2023 | 10:37 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Kinnate Biopharma's Q3 losses were less than expected, which could be seen as a positive sign by investors.
Kinnate Biopharma reported lower than expected losses for Q3, which is generally seen as a positive sign by investors. This could lead to increased investor confidence and potentially a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100